Atezolizumab (anti-PD-L1) and bevacizumab (vascular endothelial growth factor (VEGF) inhibitor) have been shown to be efficacious (86, 87), and their combination has demonstrated antitumor activity and safety in a phase 1b trial in patients with unresectable hepatocellular carcinoma. The gene discussed is CD274; the disease is hepatocellular carcinoma.